---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Dosage"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Dosage. Topics: Dose supporting the marketing applications: 36-month data from high-dose participants and Single administration: one dose given during a neurosurgical visit. 2 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/dosage"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Dose supporting the marketing applications: 36-month data from high-dose participants

> “The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.10.1-2"></a>

### Single administration: one dose given during a neurosurgical visit

> “It is important to reiterate that AMT-130 is administered only once.”
> “AMT-130 is administered once by neurosurgical procedure.”
> “This investigational treatment is the first one-time administered gene therapy to enter clinical testing for the treatment of HD.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

> “AMT-130 is administered one time with potentially long-term effects.”

Source: [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)

<a id="topic-2.1.2.10.1-3"></a>

### Infusion volume and concentration of the clinical dose

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
